BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8649785)

  • 21. Familial gastric cancer and Li-Fraumeni syndrome.
    Corso G; Pedrazzani C; Marrelli D; Pinto E; Roviello F
    Eur J Cancer Care (Engl); 2010 May; 19(3):377-81. PubMed ID: 19674071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
    Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
    Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 mutation and haplotype analysis of two large African American families.
    Hung J; Mims B; Lozano G; Strong L; Harvey C; Chen TT; Stastny V; Tomlinson G
    Hum Mutat; 1999; 14(3):216-21. PubMed ID: 10477429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early detection of adrenocortical carcinoma in a child with Li-Fraumeni syndrome.
    Lin MT; Shieh JJ; Chang JH; Chang SW; Chen TC; Hsu WH
    Pediatr Blood Cancer; 2009 Apr; 52(4):541-4. PubMed ID: 19101993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome.
    Watanabe T; Vital A; Nobusawa S; Kleihues P; Ohgaki H
    Acta Neuropathol; 2009 Jun; 117(6):653-6. PubMed ID: 19340432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Balanced t(11;15)(q23;q15) in a TP53+/+ breast cancer patient from a Li-Fraumeni syndrome family.
    Sherif ZA; Danielsen M
    Cancer Genet Cytogenet; 2006 Jul; 168(1):50-8. PubMed ID: 16772121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline TP53 mutations and Li-Fraumeni syndrome.
    Varley JM
    Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.
    Lee SB; Kim SH; Bell DW; Wahrer DC; Schiripo TA; Jorczak MM; Sgroi DC; Garber JE; Li FP; Nichols KE; Varley JM; Godwin AK; Shannon KM; Harlow E; Haber DA
    Cancer Res; 2001 Nov; 61(22):8062-7. PubMed ID: 11719428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene.
    Bougeard G; Brugières L; Chompret A; Gesta P; Charbonnier F; Valent A; Martin C; Raux G; Feunteun J; Bressac-de Paillerets B; Frébourg T
    Oncogene; 2003 Feb; 22(6):840-6. PubMed ID: 12584563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family.
    Schiffman JD; Chun N; Fisher PG; Dahl GV; Ford JM; Eggerding FA
    Pediatr Blood Cancer; 2008 Apr; 50(4):914-6. PubMed ID: 17554785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Li-Fraumeni syndrome in a Malaysian kindred.
    Ariffin H; Martel-Planche G; Daud SS; Ibrahim K; Hainaut P
    Cancer Genet Cytogenet; 2008 Oct; 186(1):49-53. PubMed ID: 18786442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
    Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [When is it useful to look for TP53 germline gene mutations in families of oncology patients?].
    Trková M; Sedlácek Z
    Cas Lek Cesk; 2003; 142(4):220-5. PubMed ID: 12841124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families.
    Bougeard G; Sesboüé R; Baert-Desurmont S; Vasseur S; Martin C; Tinat J; Brugières L; Chompret A; de Paillerets BB; Stoppa-Lyonnet D; Bonaïti-Pellié C; Frébourg T;
    J Med Genet; 2008 Aug; 45(8):535-8. PubMed ID: 18511570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss origin.
    Bendig I; Mohr N; Kramer F; Weber BH
    Cancer Genet Cytogenet; 2004 Oct; 154(1):22-6. PubMed ID: 15381368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours.
    Sedlacek Z; Kodet R; Kriz V; Seemanova E; Vodvarka P; Wilgenbus P; Mares J; Poustka A; Goetz P
    Br J Cancer; 1998 Apr; 77(7):1034-9. PubMed ID: 9569035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature.
    Agarwalla PK; Dunn IF; Turner CD; Ligon KL; Schneider KA; Smith ER
    Pediatr Neurosurg; 2008; 44(6):501-8. PubMed ID: 19127094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
    Salmon A; Amikam D; Sodha N; Davidson S; Basel-Vanagaite L; Eeles RA; Abeliovich D; Peretz T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):490-3. PubMed ID: 17572079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings.
    Eeles RA; Warren W; Knee G; Bartek J; Averill D; Stratton MR; Blake PR; Tait DM; Lane DP; Easton DF
    Oncogene; 1993 May; 8(5):1269-76. PubMed ID: 8479749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.